Percent of prostate needle biopsy cores with cancer is a significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: Results from the search database

被引:76
作者
Freedland, SJ
Aronson, WJ
Terris, MK
Kane, CJ
Amling, CL
Dorey, F
Presti, JC
机构
[1] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA
[3] Vet Affairs Greater Los Angeles Hlth Care Syst, Dept Surg, Los Angeles, CA USA
[4] Stanford Univ, Med Ctr, Urol Sect,Sch Med, Vet Affairs Palo Alto Hlth Care Syst,Dept Urol, Palo Alto, CA 94304 USA
[5] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA
[6] USN, Ctr Med, San Diego, CA 92152 USA
关键词
prostatic neoplasms; prostatectomy; biopsy; needle; prostate-specific antigen; recurrence;
D O I
10.1097/01.ju.0000065588.82511.06
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Recent studies have suggested that the percent of positive cores in the prostate needle biopsy is a significant predictor of outcome among men undergoing radical prostatectomy or radiation therapy for prostate cancer. We evaluate whether either percent of cores with cancer or percent of cores positive from the most and least involved side of the prostate needle biopsy was associated with a worse outcome among men treated with radical prostatectomy. Materials and Methods: A retrospective survey of 1,094 patients from the SEARCH Database treated with radical prostatectomy at 4 different equal access medical centers in California between 1988 and 2002 was undertaken. We used multivariate analysis to examine whether total percent of prostate needle biopsy cores with cancer, percent of cores positive from each side of the prostate and other clinical variables were significant predictors of adverse pathology and time to prostate specific antigen (PSA) recurrence following radical prostatectomy. Results: On multivariate analysis serum PSA and percent of positive cores were significant predictors of positive surgical margins, nonorgan confined disease and seminal vesicle invasion. Percent of positive cores (p <0.001), serum PSA (p = 0.008) and biopsy Gleason score (p = 0.014) were significant independent predictors of time to biochemical recurrence. On a separate multivariate analysis that included the variables of total percent of positive cores, percent of positive cores from the most involved side of the biopsy, percent of positive cores from the least involved side of the biopsy and whether the biopsy was positive unilaterally or bilaterally, only the percent of positive cores from the most involved side of the biopsy was a significant independent predictor of PSA failure following radical prostatectomy. Percent of positive cores was used to separate patients into a low risk (less than 34%), intermediate risk (34% to 50%) and high risk (greater than 50%) groups, which provided significant preoperative risk stratification for PSA recurrence following radical prostatectomy (p <0.001). Percent of positive cores cut points were able to further risk stratify men who were at low (p = 0.001) or intermediate (p = 0.036) but not high (p = 0.674) risk for biochemical failure based on serum PSA and biopsy Gleason score. Conclusions: Percent of positive cores in the prostate needle biopsy was a significant predictor of adverse pathology and biochemical failure following radical prostatectomy, and the cut points of less than 34%, 34% to 50% and greater than 50% can be used to risk stratify patients preoperatively. The finding that percent of positive cores from the most involved side of the biopsy was a stronger predictor of PSA failure than the total percent of cores involved suggests that multiple positive biopsies from a single side might be a better predictor of a larger total cancer volume and thus correlate with clinical outcome.
引用
收藏
页码:2136 / 2141
页数:6
相关论文
共 20 条
[1]   PROSTATE-SPECIFIC ANTIGEN AND GLEASON GRADE - AN IMMUNOHISTOCHEMICAL STUDY OF PROSTATE-CANCER [J].
AIHARA, M ;
LEBOVITZ, RM ;
WHEELER, TM ;
KINNER, BM ;
OHORI, M ;
SCARDINO, PT .
JOURNAL OF UROLOGY, 1994, 151 (06) :1558-1564
[2]  
[Anonymous], 1992, American Joint Committee on Cancer Staging Manual
[3]   Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies [J].
Borboroglu, PG ;
Comer, SW ;
Riffenburgh, RH ;
Amling, CL .
JOURNAL OF UROLOGY, 2000, 163 (01) :158-162
[4]   Systematic sextant biopsies in the prediction of extracapsular extension at radical prostatectomy [J].
Borirakchanyavat, S ;
Bhargava, V ;
Shinohara, K ;
Toke, A ;
Carroll, PR ;
Presti, JC .
UROLOGY, 1997, 50 (03) :373-378
[5]   Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Blank, K ;
Broderick, GA ;
Tomaszewski, JE ;
Renshaw, AA ;
Kaplan, I ;
Beard, CJ ;
Wein, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974
[6]   Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Fondurulia, J ;
Chen, MH ;
Tomaszewski, JE ;
Renshaw, AA ;
Wein, A ;
Richie, JP .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (06) :1164-1172
[7]  
D'Amico AV, 2000, MOL UROL, V4, P171
[8]   Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center [J].
Freedland, SJ ;
Jalkut, M ;
Dorey, F ;
Sutter, ME ;
Aronson, WJ .
UROLOGY, 2000, 56 (01) :87-91
[9]   Race as an outcome predictor after radical prostatectomy: Results from the shared equal access regional cancer hospital (search) database [J].
Freedland, SJ ;
Amling, CL ;
Dorey, F ;
Kane, CJ ;
Presti, JC ;
Terris, MK ;
Aronson, WJ .
UROLOGY, 2002, 60 (04) :670-674
[10]   Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score [J].
Freedland, SJ ;
Csathy, GS ;
Dorey, F ;
Aronson, WJ .
JOURNAL OF UROLOGY, 2002, 167 (02) :516-520